Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors.

24 However, treatment of mice with single-agent lefitolimod in the syngeneic EMT-6 breast cancer model showed substantial tumor growth inhibition and a highly significant increase of survival ( Figure 4(e,f) ).

also in 132,142 other papers